Drug Information

Drug (ID: DG01472) and It's Reported Resistant Information

• Name: Staurosporine
• Synonyms: Staurosporine; Staurosporin; 62996-74-1; (+)-Staurosporine; Antibiotic 230; Antibiotic AM 2282; AM-2282; CCRIS 3272; Antibiotic AM-2282; UNII-H88EPA0A3N; Alkaloid AM-2282 from Streptomyces; H88EPA0A3N; CHEMBL388978; CHEBI:15738; 8,12-Epoxy-1H,8H-2,7b,12a-triazadibenzo(a,g)cyclonona(cde)trinden-1-one, 2,3,9,10,11,12-hexahydro-9-methoxy-8-methyl-10-(methylamino)-, (8alpha,9beta,10beta,12alpha)-(+)-; (5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-17-oxa-4b,9a,15-triaza-5,9-methanodibenzo[b,h]cyclonona[jkl]cyclopenta[e]-as-indacen-14-one; (5S,6R,7R,9R)-6-methoxy-5-methyl-7-methylamino-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; GNF-PF-1389; methoxy-methyl-(methylamino)[ ]one; SR-00000001485; Staurosporin, 4; 1nvr; 1stc; 1xbc; 1xjd; 1yhs; 2gcd; Staurosporine, 8; CGP 39360; Staurosporine & TNF; 1q3d; 1sm2; 2dq7; MolMap_000047; SCHEMBL8157; CBiol_001978; BSPBio_001146; GTPL346; BDBM2579; MEGxm0_000307; DTXSID6041131; 1u59; BCPP000063; Bio1_000264; Bio1_000753; Bio1_001242; HMS1990J07; HMS3650B17; EX-A1777; ZINC3814434; AM2282; NSC755774; s1421; AKOS015897119; AM 2282; CCG-208052; DB02010; NSC-755774; QTL1_000078; NCGC00162400-01; NCGC00162400-02; NCGC00162400-03; NCGC00162400-04; NCGC00162400-05; NCGC00162400-06; NCGC00162400-09; 9,13-Epoxy-1H,9H-diindolo(1,2,3-gh:3',2',1'-lm)pyrrolo(3,4-j)(1,7)-benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S-(9alpha,10beta,11beta,13alpha)-; HY-15141; Staurosporine & Tumor necrosis factor (TNF); Staurosporine 100 microg/mL in Acetonitrile; Q5957181; SR-00000001485-4; BRD-K17953061-001-02-8; BRD-K17953061-001-04-4; BRD-K17953061-001-05-1; BRD-K17953061-001-08-5; BRD-K17953061-001-10-1; BRD-K17953061-001-11-9; (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8(13),9,11,14(28),15(19),20(27),21(26),22,24-nonaen-16-one; (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.1^{2,6}.0^{7,28}.0^{8,13}.0^{15,19}.0^{20,27}.0^{21,26}]nonacosa-8,10,12,14(28),15(19),20(27),21,23,25-nonaen-16-one; (2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one; (5S,6R,7R,9R)-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; [9S-(9 ,10 ,11 ,13 )]-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; 109189-95-9; 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S,10R,11R,13R)- & Tumor necrosis factor (TNF); 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, (9S,10R,11R,13R)- (9CI); 9,13-Epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one, 2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-, [9S-(9alpha,10beta,11beta,13alpha)]-
• Indication:
  In total 1 Indication(s)
  Bacterial infection [ICD-11: 1A00-1C4Z]; Investigative; [1]
• Target: Bacterial Penicillin binding protein (Bact PBP); NOUNIPROTAC; [1]
• Formula: 2
• IsoSMILES: C[C@@]12[C@@H]([C@@H](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)NC)OC
• InChI: InChI=1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
• InChIKey: HKSZLNNOFSGOKW-FYTWVXJKSA-N
• PubChem CID: 44259
• ChEBI ID: CHEBI:15738
• TTD Drug ID: D0C2YB
• INTEDE ID: DR00790
• DrugBank ID: DB02010

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Lung cancer [ICD-11: 2C25]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Epidermal growth factor receptor (EGFR) [1]

• Sensitive Disease: Lung adenocarcinoma [ICD-11: 2C25.0]
• Molecule Alteration: Missense mutation; p.T790M (c.2369C>T)
• Wild Type Structure: Method: X-ray diffraction; Resolution: 3.10 Å; PDB: 2J6M
• Mutant Type Structure: Method: X-ray diffraction; Resolution: 3.05 Å; PDB: 2JIU

RMSD: 1.57; TM score: 0.92063; Amino acid change: T790M

• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Lung; N.A.

ICD-X: Extension Codes

Streptococcus suis [ICD-11: XN5SE]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Serine/threonine-protein kinase (SSTK) [2]

• Sensitive Disease: s. suis infection [ICD-11: XN5SE]
• Molecule Alteration: Phosphorylation; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Streptococcus suis SC19; 5833
• Experiment for Molecule Alteration: High-throughput screening assay; In vitro ssSTK autophosphorylation assay
• Experiment for Drug Resistance: Virulence assay; IC50 assay; Bacterial growth assay
• Mechanism Description: In this study, we firstly identified the Thr167 and Ser175 residues in the activation loop of S. suis STK (ssSTK) as the kinase autophosphorylation sites. Phenotyping results demonstrated that the autophosphorylation deficient strain resembled the stk deletion strain showing essentiality for bacterial growth in minimal medium, abnormal morphology, and decreased virulence when compared with the wild-type S. suis SC19 strain. Based on these findings, we established an ssSTK inhibitor screening approach by measuring the growth of S. suis in a minimal medium and testing the autophosphorylation inhibition by measuring the consumption of ATP in an enzymatic reaction by ssSTK. A series of inhibitors against ssSTK are identified from a commercial kinase inhibitors library, including Staurosporine, K252a, AT9283, and APY29. These inhibitors showed antimicrobial activity in vitro. Moreover, by using Galleria mellonella larvae infection assay, compound APY29 displayed in vivo efficacy against S. suis infection. Additionally, it was predicted by molecular docking that these inhibitors could interact with ssSTK. Collectively, our data illustrated the essential roles of ssSTK autophosphorylation in the physiology and pathogenicity of S. suis and consider these inhibitors as promising antimicrobial lead compounds.

References

• Ref 1: A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivityAmino Acids. 2014 Jul;46(7):1635-48. doi: 10.1007/s00726-014-1716-0.
• Ref 2: Inhibitors targeting the autophosphorylation of serine/threonine kinase of Streptococcus suis show potent antimicrobial activity. Front Microbiol. 2022 Sep 2;13:990091.